 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12345678910111213...1920» |
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice (clinicaltrials.gov) - Aug 9, 2023
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial primary completion date: Apr 2023 --> Aug 2023
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice (clinicaltrials.gov) - Aug 9, 2023
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial primary completion date: Apr 2023 --> Aug 2023 Trial primary completion date: Apr 2023 --> Jan 2024
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, dapagliflozin/semaglutide (NN9917) / Novo Nordisk
Trial completion: A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet (clinicaltrials.gov) - Aug 9, 2023
P1, N=152, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Apr 2023 --> Jan 2024 Recruiting --> Completed
- || orforglipron (OWL833) / Eli Lilly
P2 data, Journal: Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. (Pubmed Central) - Aug 7, 2023
P2
The adverse event profile was similar to other GLP-1 receptor agonists in similar stage of development. Orforglipron might provide an alternative to injectable GLP-1 receptor agonists and oral semaglutide, with the prospect of less burdensome administration to achieve treatment goals in people with type 2 diabetes.
- || Rybelsus (semaglutide oral) / Novo Nordisk
News on @novonordisk's Rybelsus,https://t.co/eSHA9ZWcBk. Vivisum Partners provides insights on Rybelus in its own Brand Landscape, https://t.co/5sW1RVzTjD covering the PHYCURE dimensions and comparing it to other Oral #T2D treatments. #biopharma #research #branding (Twitter) - Aug 3, 2023
- || lotiglipron (PF-07081532) / Pfizer
Trial completion date, Trial primary completion date: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity (clinicaltrials.gov) - Aug 1, 2023
P2, N=902, Active, not recruiting, Sponsor: Pfizer
Orforglipron might provide an alternative to injectable GLP-1 receptor agonists and oral semaglutide, with the prospect of less burdensome administration to achieve treatment goals in people with type 2 diabetes. Trial completion date: Dec 2023 --> Aug 2023 | Trial primary completion date: Nov 2023 --> Jun 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Enrollment change: Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data (clinicaltrials.gov) - Jul 31, 2023
P=N/A, N=2316, Completed, Sponsor: Brigham and Women's Hospital
Trial completion date: Dec 2023 --> Aug 2023 | Trial primary completion date: Nov 2023 --> Jun 2023 Active, not recruiting --> Completed | N=1356 --> 2316
- PN127. Breaking News: GLP-1 agonists, SGLT2 inhibitors, CNS Stimulants - Perioperative Implications (South: 205/206) - Jul 20, 2023 - Abstract #ASA2023ASA_664;
Examples of GLP-1 RAs include exenatide (twice-daily and extended-release once-weekly), lixisenatide (once-daily), liraglutide (once-daily), dulaglutide (once-weekly), semaglutide (once-weekly), and oral semaglutide (once-daily)...During this panel, our experts will dissect the multifaceted impact of these medications on anesthetic care and patient safety, offering a comprehensive overview of their perioperative implications. Join us as we navigate the forefront of medical innovation and its intricate connection to the world of anesthesia.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal: Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus (Pubmed Central) - Jul 18, 2023
Join us as we navigate the forefront of medical innovation and its intricate connection to the world of anesthesia. The presented review describes benefits in glycemic control as well as in the reduction of relative cardiovascular event risks with GLP-1RA treatment in the Asian population, which requires further in-depth research and implies optimal management tactics in patients with T2DM.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date: PIONEER TEENS: A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (clinicaltrials.gov) - Jul 12, 2023
P3, N=132, Recruiting, Sponsor: Novo Nordisk A/S
The presented review describes benefits in glycemic control as well as in the reduction of relative cardiovascular event risks with GLP-1RA treatment in the Asian population, which requires further in-depth research and implies optimal management tactics in patients with T2DM. Trial completion date: Feb 2025 --> Aug 2025
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Trial completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India (clinicaltrials.gov) - Jul 12, 2023
P=N/A, N=388, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial completion date: Feb 2025 --> Aug 2025 Not yet recruiting --> Enrolling by invitation | Trial completion date: Dec 2023 --> May 2024
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets (clinicaltrials.gov) - Jul 12, 2023
P1, N=14, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Enrolling by invitation | Trial completion date: Dec 2023 --> May 2024 Recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> May 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal: Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India. (Pubmed Central) - Jul 11, 2023
Recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> May 2023 In this small cohort of patients, the metrics of short-term glycemic control and the extrapolated HbA1C values were similar for the daily 7 mg dose versus the alternate-day 14 mg dose
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Safety profile of semaglutide in people aged 55 years and over: pooled data from the PIONEER, SUSTAIN and STEP phase 3 clinical programmes (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3849;
P3
In this small cohort of patients, the metrics of short-term glycemic control and the extrapolated HbA1C values were similar for the daily 7 mg dose versus the alternate-day 14 mg dose Safety data for participants ?55 years were pooled for: people with T2D receiving once-daily oral semaglutide 3, 7 or 14 mg versus comparator (active or placebo) for 26?78 weeks in PIONEER 1?5 and 7?10 (PIONEER pool, N=4186); people with T2D receiving once-weekly subcutaneous semaglutide 0.5 or 1 mg versus comparator (active or placebo) for 30?56 weeks in SUSTAIN 1?5 and SUSTAIN Japan (NCT02207374 and NCT02254291; SUSTAIN pool, N=2825); and people with overweight/obesity (with/without T2D) receiving once-weekly subcutaneous semaglutide 2.4 mg versus placebo for 68?104 weeks in STEP 1
- || Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Review, HEOR, Cost-effectiveness, Cost effectiveness: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus. (Pubmed Central) - Jul 6, 2023
The included CEAs using DAMs have limitations that hinder their ability to inform decision makers on the cost-effective choice: lack of updated reasoning behind the choice of key model assumptions, over-reliance on risk equations based on older treatment practices, and sponsorship bias. The question of which NIAD is cost effective for the treatment of which T2DM patient is a pressing one and the answer remains unclear.
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: Only one reported case of severe cholestatic DILI from oral semaglutide needing OLT. What is lotiglipron DILI signature @pfizer Progressive Cholestasis and Biliary Cirrhosis After Initiating Oral Semaglutide: Report From the Drug-Induced Liver… https://t.co/RVPQh3FEAq (Twitter) - Jul 6, 2023
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) (clinicaltrials.gov) - Jul 5, 2023
P3, N=1840, Active, not recruiting, Sponsor: Novo Nordisk A/S
The question of which NIAD is cost effective for the treatment of which T2DM patient is a pressing one and the answer remains unclear. Recruiting --> Active, not recruiting
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) (clinicaltrials.gov) - Jul 5, 2023
P3, N=1840, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Very exciting about promising new oral GLP-1 data presented at #ADA2023. But a total miss by @nytimes on the headline since there is already a pill form of Ozempic called Rybelsus. https://t.co/B37slewX33 (Twitter) - Jun 26, 2023
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) (clinicaltrials.gov) - Jun 26, 2023
P3, N=230, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
En #ADA2023 momentos excitantes, se presentan resultados del OASIS 1 y PIONEER PLUS, ensayos enfocados a semaglutide vía oral en el manejo del peso. (Twitter) - Jun 25, 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Ozempic and more recently Rybelsus (Twitter) - Jun 24, 2023
- || Rybelsus (semaglutide oral) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi, Trulicity (dulaglutide) / Eli Lilly
Retrospective data, Review, Journal: GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Jun 19, 2023
GLP-1RAs, particularly longer-acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes. (Pubmed Central) - Jun 15, 2023
Several large clinical studies, the bulk of which are cardiovascular outcome trials, show that GLP-1 RA treatment is safe and tolerated for persons with T2DM and impaired renal function and that it may potentially have renoprotective characteristics. This article focuses on the advances of oral GLP1-RA and describes the key milestones and predicted advantages.
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P2 trial: Clinical Trial of Rybelsus (semaglutide) Among Adults with Alcohol Use Disorder (AUD) (clinicaltrials.gov) - Jun 7, 2023
P2, N=135, Not yet recruiting, Sponsor: University of Colorado, Denver
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, NNC0385-0434 / Novo Nordisk
Trial completion: A Research Study Looking at New Protein-based Tablets in Healthy Male Participants (clinicaltrials.gov) - Jun 7, 2023
P1, N=384, Completed, Sponsor: Novo Nordisk A/S
This article focuses on the advances of oral GLP1-RA and describes the key milestones and predicted advantages. Recruiting --> Completed
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) (clinicaltrials.gov) - Jun 6, 2023
P3, N=230, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, Journal: Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL, a randomized trial, design and baseline characteristics. (Pubmed Central) - Jun 5, 2023
Recruiting --> Completed SOUL will provide evidence regarding the CV effects of oral semaglutide in individuals with type 2 diabetes and established ASCVD and/or CKD.
- | Rybelsus (semaglutide oral) / Novo Nordisk
That’s like 4 rybelsus 14 mg tablets ( highest dose available) (Twitter) - Jun 1, 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Oral Semaglutide Led to Similar Weight Loss as Injection, Company Says. (Pubmed Central) - May 31, 2023
SOUL will provide evidence regarding the CV effects of oral semaglutide in individuals with type 2 diabetes and established ASCVD and/or CKD. No abstract available
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (clinicaltrials.gov) - May 31, 2023
P3, N=667, Completed, Sponsor: Novo Nordisk A/S
No abstract available Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care (clinicaltrials.gov) - May 25, 2023
P4, N=12, Terminated, Sponsor: Sansum Diabetes Research Institute
Active, not recruiting --> Completed N=100 --> 12 | Trial completion date: Dec 2023 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Feb 2023; Principal Investigator no longer at study site.
- || Rybelsus (semaglutide oral) / Novo Nordisk
I notice in india only oral semaglutide is available (Twitter) - May 23, 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. (Pubmed Central) - May 16, 2023
N=100 --> 12 | Trial completion date: Dec 2023 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Feb 2023; Principal Investigator no longer at study site. The goal of this study was to examine the effects of semaglutide on biobehavioral correlates of alcohol use in rodents, using psychopharmacology and electrophysiology experiments...In alcohol-na
- Rybelsus (semaglutide oral) / Novo Nordisk
Oral Semaglutide, effectiveness, safety and tolerability in real life: a short-term retrospective observational study. (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1767;
Oral SEMA at medium doses is effective in the short term with 1% reductions in HbA1c, 5% weight loss and a significant reduction in microalbuminuria. Oral SEMA is usually started in obese PLWT2D na
- Rybelsus (semaglutide oral) / Novo Nordisk
Oral Glucagon-like Peptide Receptor Agonist-1 as Adjuvant Treatment in HNF1A-MODY (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1538;
After initiation of oral semaglutide, her glimepiride was reduced to 2 mg once daily, her HbA1c improved to 5.4%, and she lost 30 lbs over a 6-month timeframe. This is the first report demonstrating the benefits of oral GLP-1 RA treatment in a patient with HNF1A-MODY, and this clinical case provides further support of use GLP-1 RA use as adjuvant treatment to sulfonylurea in patients with HNF1A-MODY.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal: Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality? (Pubmed Central) - May 8, 2023
It revealed no difference in TIR, TAR, and TBR between the two groups (days-on-drug and days-off-drug). Conclusion Throughout the period of observation, the glycemic metrics (TIR, TAR, and TBR) remained steady with a 14 mg alternate-day oral semaglutide regimen.
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: PIONEER TEENS: A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (clinicaltrials.gov) - May 8, 2023
P3, N=132, Recruiting, Sponsor: Novo Nordisk A/S
Conclusion Throughout the period of observation, the glycemic metrics (TIR, TAR, and TBR) remained steady with a 14 mg alternate-day oral semaglutide regimen. Active, not recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
COMPARISON OF SEMAGLUTIDE ORAL VS SUBCUTANEOUS IN CHRONIC KIDNEY DISEASE (CKD) (Focussed Oral Room 4) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1984;
oral formulation of semaglutide was equally effective in terms of glucose control and body weight in patients with T2DM and CKD even with more patients on the low-medium doses. Gi side effects were similar with both formulations though the lower number of patients on the higher oral dose does not allow further conclusions Subcutaneous vs oral semaglutide in T2DM CKD patients Sbc semaglutide Oral semaglutide p n 50 n 20 Male % 80 75 0.6 Age (y) 68.5 (SD 10.1) 68.8 (SD 7.0) 0.9 eGFR (ml/min/1.73m2) 48.4 (SD 20.8) 50.5 (SD 19.5) 0.8 143.1 [33.5-723.8] 280.7 [79.9-462.6] 0.6 -6.2 [-10.8, 0] -6.2 [-11.5 0] 0.9 UACr (mg/g) HbA1C% reduction BMI% reduction -6.5 [ -9.0, -2.0] -3.8 [ -4.7, 0] 0.07 Weight loss % -6.4 [-8.7, -1.4] -4.1 [-6.0, 0] 0.2 eGFR difference basal-final ((ml/min/1.73m2) 0 [-4 , 4] -1 [-5, 3] 0.5 UACR difference (basal-final) (mg/g) 2.7 [ -96.5 a 120] 2.2 [-133.8 a 239.0] 0.8 SBP difference (basal-final) (mmHg) 0 [-4 a 5] -1.5 [-10 a a 0] 0.5 DBP difference (basal-final) (mmHG) 0 [-5 a 0] 0 [-10 a 0] 0.6
- ||| lotiglipron (PF-07081532) / Pfizer
Enrollment closed: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity (clinicaltrials.gov) - May 3, 2023
P2, N=900, Active, not recruiting, Sponsor: Pfizer
Gi side effects were similar with both formulations though the lower number of patients on the higher oral dose does not allow further conclusions Subcutaneous vs oral semaglutide in T2DM CKD patients Sbc semaglutide Oral semaglutide p n 50 n 20 Male % 80 75 0.6 Age (y) 68.5 (SD 10.1) 68.8 (SD 7.0) 0.9 eGFR (ml/min/1.73m2) 48.4 (SD 20.8) 50.5 (SD 19.5) 0.8 143.1 [33.5-723.8] 280.7 [79.9-462.6] 0.6 -6.2 [-10.8, 0] -6.2 [-11.5 0] 0.9 UACr (mg/g) HbA1C% reduction BMI% reduction -6.5 [ -9.0, -2.0] -3.8 [ -4.7, 0] 0.07 Weight loss % -6.4 [-8.7, -1.4] -4.1 [-6.0, 0] 0.2 eGFR difference basal-final ((ml/min/1.73m2) 0 [-4 , 4] -1 [-5, 3] 0.5 UACR difference (basal-final) (mg/g) 2.7 [ -96.5 a 120] 2.2 [-133.8 a 239.0] 0.8 SBP difference (basal-final) (mmHg) 0 [-4 a 5] -1.5 [-10 a a 0] 0.5 DBP difference (basal-final) (mmHG) 0 [-5 a 0] 0 [-10 a 0] 0.6 Recruiting --> Active, not recruiting
- ID110521156 / Ildong
Discovery of ID110521156, a Small Molecule GLP-1 Receptor Agonist, for the Treatment of Type 2 Diabetes and Obesity (Poster Halls B-C; [Board No. 93]) - Apr 29, 2023 - Abstract #ADA2023ADA_3124;
ID110521156 demonstrated no liabilities when tested on a battery of safety pharmacology studies, including cardiovascular, respiratory, and neurobehavioral function assessment. No genotoxicity was observed on Ames, in vitro chromosomal aberration, and in vivo micronucleus test.From these nonclinical study results, ID110521156 might be considered as a potent candidate of small molecule selective GLP-1 receptor agonist to treat type 2 diabetes and obesity.
- Rybelsus (semaglutide oral) / Novo Nordisk, Nodexen (exenatide oral) / NOD Pharm
Oral Delivery of a GLP-1 Agonist with High Bioavailability in Dogs and Humans (Poster Halls B-C; [Board No. 89]) - Apr 29, 2023 - Abstract #ADA2023ADA_3119;
No genotoxicity was observed on Ames, in vitro chromosomal aberration, and in vivo micronucleus test.From these nonclinical study results, ID110521156 might be considered as a potent candidate of small molecule selective GLP-1 receptor agonist to treat type 2 diabetes and obesity. While most require injections due to poor oral bioavailability, Rybelsus
- Rybelsus (semaglutide oral) / Novo Nordisk
Real-World Impact of Oral Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE (Poster Halls B-C; [Board No. 86]) - Apr 29, 2023 - Abstract #ADA2023ADA_3116;
At 12-month follow-up, adults initiating oral sema T2D had statistically significant decreases in HbA1c, weight, and BMI from baseline. Further regression analyses will be conducted to control for covariates.
- Rybelsus (semaglutide oral) / Novo Nordisk
Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BIOJET Oral Biotherapeutic Delivery Platform in Porcine Model (Poster Halls B-C; [Board No. 80]) - Apr 29, 2023 - Abstract #ADA2023ADA_3110;
This study demonstrated that administration of the BIOJET device has the potential to achieve a magnitude greater bioavailability than the currently marketed oral semaglutide (< 1%). The BIOJET device could provide an alternative for the oral administration of large molecules and may improve patient compliance.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal: Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings. (Pubmed Central) - Apr 27, 2023
Oral semaglutide may be an effective option for the intensification of therapy in Japanese patients with T2DM who have inadequate glycemic control with existing therapy. It may also reduce BW and improve cardiometabolic parameters.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice (clinicaltrials.gov) - Apr 24, 2023
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
It may also reduce BW and improve cardiometabolic parameters. Not yet recruiting --> Enrolling by invitation
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P4 trial: Additive Benefits of Semaglutide for open-AngLe glaucoma (EUDRACT) - Apr 18, 2023
P4, N=126, Ongoing, Sponsor: Department of Ophthalmology, Rigshospitalet
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial: Semaglutide in Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Apr 14, 2023
P4, N=180, Recruiting, Sponsor: Zagazig University
- Rybelsus (semaglutide oral) / Novo Nordisk
Safety and efficacy of oral semaglutide in overweight diabetic patients with non-alcoholic fatty liver disease: an interim analysis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1952;
There was a significant reduction in BMI, ALT, liver stiffness, CAP and lipid profile. There were no significant treatment-emergent adverse events.
- Rybelsus (semaglutide oral) / Novo Nordisk
Impact of oral semaglutide on liver pathology and glucose metabolism in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1936;
In patients with NAFLD complicated by T2DM, oral semaglutide may improve hepatic steatosis/inflammation and serum lipid metabolism as well as improve glucose metabolism and decrease body weight. Figure: none.